Based on the Hookipa Pharma Inc stock forecast from 2 analysts, the average analyst target price for Hookipa Pharma Inc is USD 11.00 over the next 12 months. Hookipa Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Hookipa Pharma Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Hookipa Pharma Inc’s stock price was USD 1.25. Hookipa Pharma Inc’s stock price has changed by -6.72% over the past week, -33.86% over the past month and -82.99% over the last year.
No recent analyst target price found for Hookipa Pharma Inc
No recent average analyst rating found for Hookipa Pharma Inc
Company Overview Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York. Read Less
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizuma...Read More
Frequently Asked Questions About Hookipa Pharma Inc (HOOK) Stock
Based on ratings from 2 analysts Hookipa Pharma Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on HOOK's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for HOOK is USD 11.00 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on HOOK's stock to indicate if its overvalued.
The last closing price of HOOK's stock was USD 1.25.
The most recent market capitalization for HOOK is USD 0.02B.
Based on targets from 2 analysts, the average taret price for HOOK is projected at USD 11.00 over the next 12 months.
This means that HOOK's stock price may go up by +780.00% over the next 12 months.
We can't find any ETFs which contains Hookipa Pharma Inc's stock.
As per our most recent records Hookipa Pharma Inc has 151 Employees.
Hookipa Pharma Inc's registered address is 350 Fifth Avenue, New York, NY, United States, 10118.
You can get more information about it from Hookipa Pharma Inc's website at https://www.hookipapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Hookipa Pharma Inc (HOOK) Stock
Based on ratings from 2 analysts Hookipa Pharma Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on HOOK's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for HOOK is USD 11.00 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on HOOK's stock to indicate if its overvalued.
The last closing price of HOOK's stock was USD 1.25.
The most recent market capitalization for HOOK is USD 0.02B.
Based on targets from 2 analysts, the average taret price for HOOK is projected at USD 11.00 over the next 12 months.
This means that HOOK's stock price may go up by +780.00% over the next 12 months.
We can't find any ETFs which contains Hookipa Pharma Inc's stock.
As per our most recent records Hookipa Pharma Inc has 151 Employees.
Hookipa Pharma Inc's registered address is 350 Fifth Avenue, New York, NY, United States, 10118.
You can get more information about it from Hookipa Pharma Inc's website at https://www.hookipapharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HOOK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
